Pinnacle Food Revenue Reached $3.41 Million in 2025 as Company Swung to a Loss
Key Facts
No announcement that Pinnacle Food Group had appointed a strategic adviser for mergers and acquisitions appeared on the company news page reviewed, and the newswire link provided could not be opened. The adviser’s name, the date the engagement began and the responsibilities attributed to it in the earlier draft therefore could not be confirmed. The matter comes amid a broader strategy the company announced in March 2026, when it said it was pursuing inorganic growth by identifying high-quality, fragmented assets in synthetic biology and bringing them onto its platform. The company has described itself as operating in smart agriculture and bioengineering, offering farming-as-a-service solutions and developing biology-based platforms to support efficient, sustainable food systems. Acquisitions therefore remain part of a previously announced strategy, but the available record does not establish that the reported adviser appointment took place.
In its annual report filed with the U.S. Securities and Exchange Commission, Pinnacle said revenue rose to $3,413,062 in the year ended Dec. 31, 2025, from $3,289,862 in 2024. But the modest revenue improvement coincided with a sharp reversal in the bottom line: the company posted a net loss of $1,903,908 in 2025, after recording net income of $286,142 the previous year. The figures provide financial context for the expansion strategy outlined by the company, without establishing a link between its results and the unverified appointment report. The filing also showed a notable reliance on a small number of customers: its three largest customers accounted for 36%, 29% and 18% of total revenue, respectively, in 2025. Those percentages highlight revenue concentration within the customer base recorded that year, as the company pursues its stated plan to expand its platform.
In its strategic presentation, the company said it was advancing toward the precision fermentation market, which it valued at $36 billion, with an initial focus on commercializing recombinant human lactoferrin. This puts its bioengineering business alongside farming as a service in the company’s view of its model, rather than limiting it to smart agriculture alone. The company expected its farming-as-a-service business to support double-digit annual revenue growth in fiscal 2026. That remains a company forecast, while audited figures showed annual revenue of $3,413,062 in 2025, compared with $3,289,862 in 2024. In trading on Oct. 26, 2026, PFAI shares closed at $3.4, according to EL7 data; no data available here establishes that the close was a response to the reported adviser appointment.